NAVB Navidea Biopharmaceuticals Inc.

0.18
+0.01  (+9%)
Previous Close 0.16
Open 0.16
Price To Book 18
Market Cap 36188612
Shares 201,047,843
Volume 105,079
Short Ratio 15.55
Av. Daily Volume 616,283

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 13, 2013.
Lymphoseek
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
NAV4694
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Lymphoseek
Head and Neck Cancer
Phase 2b dosing to commence 2Q 2019.
NAV3-31
Rheumatoid arthritis

Latest News

  1. Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates
  2. Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
  3. Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates
  4. Edited Transcript of NAVB earnings conference call or presentation 7-Mar-19 10:00pm GMT
  5. Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  6. Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update
  7. Navidea Biopharmaceuticals Announces Extension of NYSE American Listing
  8. Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court
  9. Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek®
  10. Edited Transcript of NAVB earnings conference call or presentation 7-Nov-18 9:30pm GMT
  11. Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors
  12. Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer
  13. Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Event 2018
  14. Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018
  15. Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors
  16. Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty Trust, Patriot Transportation Holding, and Navidea Biopharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
  17. Navidea: 3Q Earnings Snapshot
  18. Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results
  19. Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update
  20. Navidea Biopharmaceuticals Wins Dismissal of Platinum Litigation